紫杉醇联合奥沙利铂及氟尿嘧啶与奥沙利铂联合氟尿嘧啶辅助化疗Ⅲ期胃癌D2根治术的疗效比较

Comparison of the efficacy of paclitaxel combined with oxaliplatin and fluorouracil and oxaliplatin combined with fluorouracil as adjuvant chemotherapy in the treatment of stage Ⅲ gastric cancer after D2 gastrectomy

目的比较紫杉醇联合奥沙利铂及氟尿嘧啶(POF)和奥沙利铂联合氟尿嘧啶(FOLFOX)作为Ⅲ期胃癌D2根治术后辅助化疗方案的疗效及安全性。方法回顾性分析2011年1月至2014年12月于我院肿瘤内科就诊的Ⅲ期胃癌D2根治术后的患者的临床资料,共66例。其中接受POF方案辅助化疗24例,接受FOLFOX方案化疗42例。比较这些患者无疾病生存期(DFS)以及相关不良反应。结果POF组和FOLFOX组患者中位DFS分别为16个月和11个月(HR:0.558;95%CI:0.314~0.990,P=0.046),差异有统计学意义(P<0.05)。两组的不良反应均主要为消化道反应、外周神经毒性及骨髓抑制,差异元统计学意义(P>0.05),且两组患者均能够能耐受。结论POF方案对Ⅲ期胃癌D2根治术后患者的辅助化疗优于FOLFOX方案,且不良反应多能耐受。

Objective To compare the efficacy and safety of paclitaxel combined with oxaliplatin and fluorouracil (POF)and oxaliplatin and fluorouraeil (FOLFOX)as adjuvant chemotherapy in the treatment of stage Ⅲ gastric cancer after D2 gastrectomy.Methods Retrospective analysis was performed using clinical data from 66 patients with stage Ⅲ gastric cancer after D2 gastreetomy in our hospital from January 2011 to December 2014.The patients were divided into two groups according to their treatment regimens :a POF group (n =24)and an FOLFOX group (n =42).Then,the two groups were compared for disease free survival (DFS)and adverse reactions.Results The DFS was 16 months for the POF group and Ⅲ months for the FOLFOX group (HR:0.558;95%.CI:0.314-0.990;P =0.046).The main adverse reactions of the two groups were gastrointestinal reaction,peripheral neurotoxicity and myelosuppression,without statistical difference (P >0.05),and both groups were able to tolerate.Conclusions POF regimen is superior to FOLFOX as adjuvant chemotherapy for patients with stage Ⅲ gastric cancer after D2 radical resection,with tolerable adverse reactions.